Recent medical research breakthroughs have generated an unprecedented opportunity for potential new therapies—from genetic modifications to novel proteins—to address unmet needs in many medical areas like blindness and paralysis. At the March 19 WHIPgroup Meetup, Erika Smith of New Haven-based ReNetX Bio, will explore the science behind this new generation of biotech advancements and the opportunities for patients, researchers and investors.
Erika Smith is CEO of ReNetX Bio, a biotech firm that has created first in class therapeutics to treat injury/damage to the central nervous system (CNS) in conditions such as spinal cord injury (SCI), stroke and glaucoma. Ms. Smith has spent her career advancing entrepreneurs and investing in tech and biotech innovation. She was previously the Director for the $25 Million USD Blavatnik Fund for Innovation at Yale and was part of the leadership team at Yale Entrepreneurial Institute.
Recently, WHIPGROUP engaged in an arbitration that included a five day hearing in the City. Here are some thoughts about why arbitration is different (not clearly better or worse) than litigation. Venue The AAA arbitral [Read More…]
WHIPGroup previously filed a Motion to Dismiss a patent infringement suit filed against its client TomTom in the Western District of Texas. Rather than opposing WHIPGroup’s motion to dismiss, Plaintiff MDSP Technologies LLC voluntarily dismissed [Read More…]
WHIPgroup succeeded in having anticipation and indefiniteness rejections overturned by the Patent Trial and Appeal Board (PTAB). The claimed invention relates to a sequencing station that manages both sequencing and restacking tasks. The Examiner had [Read More…]